Prothrombin Complex Concentrate Market Outlook 2030
Prothrombin complex concentrate is a medication made up of blood clotting factors, II, IX, and X. They are used for factor II or X replacement in patients with congenital and acquired deficiencies. Prothrombin complex concentrate comes from the ion exchange chromatography of large plasma pools post removal of the antithrombin and factor XI. Removal of factor XI from prothrombin complex concentrate makes it applicable for prevention of bleeding in hemophilia B.
COVID-19 Impact Analysis
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness a significant growth in the future, owing to the demand for vaccine and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the prothrombin complex concentrate market.
Top Impacting Factors
Use of Warfarin for Rapid Market Expansion
Ever since its inception in mid 1900s, warfarin has become the most commonly used oral anticoagulant in patients suffering from thrombosis. Along with warfarin, the global market sales of anti-thrombotic drugs account for approximately 3% of total drug sales and are expected to increase further more.
Competitive Advantage of Prothrombin Complex Concentrate over Fresh frozen plasma (FFP) and other related Therapies
Usage of FFP and other therapies poses a risk of transfusion reaction and volume overload. In addition, FFP is rarely able to normalize INR. In contrast, prothrombin complex concentrate offers an effective option of INR normalization in addition to reduced risk of pathogen transmission.
Thrombotic Complications associated with Prothrombin Complex Concentrate
At times prothrombin complex concentrate administration leads to blood clots, which, in turn, may lead to microvascular thrombosis, disseminated intravascular coagulation, and myocardial infarction. The risk of thrombotic complications may be increased due to reasons, including underlying diseases, high prothrombin complex concentrate dosing, and unbalanced constituents.
Association with Thrombogenic Events
The primary safety concern associated with PPC is the occurrence of stroke, myocardial infractions, and deep vein thrombosis.
Key Market Trends
- One of the key driving factors of the growth of the global prothrombin complex concentrate market in North Europe is the rapidly ageing population. This poses a serious threat of liver diseases among these people, and prothrombin complex concentrate has proved to be an effective therapy in treating people with liver problems.
- Germany will lead among Europe market in 2021, due to rising cases of Hemophilia B in the country
- Another important trend includes the focus on expansion of network of plasma centers. Global players have been eyeing at acquisitions of domestic companies to get access to their plasma centers. A recent example of this includes the acquisition of U.S. branch of Biotest Pharmaceuticals Corporation by Grifols S.A.
- North America with a $260 million revenue generation FY is expected to propel the growth of the global prothrombin complex concentrate market, owing to the presence of major global players in the region.
- Rapid increase in the number of plasma centers in Southeast Asia, including China and India will enable to region to grow at an impressive CAGR by 2028.
- Recently, British Committee for Standards in Haematology has prescribed guidelines for administration of prothrombin complex concentrate to cure hemophiliacs. This provides a positive thrust for the whole pharmaceutical market.
Key Benefits of the Report
- This study presents the analytical depiction of the prothrombin complex concentrate market along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the Prothrombin Complex Concentrate market share.
- The current market is quantitatively analyzed to highlight the market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed analysis depending on competitive intensity and how the competition will take shape in the coming years.
Questions Answered in the Adenovirus Diagnostic Testing Report
- Which are the leading players active in the prothrombin complex concentrate market?
- How is each segment of the market expected to grow during the forecast period?
- What are the adoption trends for the prothrombin complex concentrate market in emerging economies and established economies across the world?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps?
- What are the impacts of COVID-19 in the industry?
- What is prothrombin complex concentrate?
- What is the prothrombin complex concentrate market prediction in the future?
- What are the current trends and predicted trends?
Prothrombin Complex Concentrate (PCC) Market Report Highlights
| Aspects | Details |
 By Product |
|
 By Applications |
|
 By End User |
|
 By Region |
|
 Key Market Players | Kedrion S.p.A, Takeda Pharmaceuticals Ltd, OCTA Pharma AG, CSL Behring GmbH, Insud pharma, China Biological Products Holding, Grifols S.A., Biotest, Abeona Therapeutics, Sanquin |
Loading Table Of Content...
